Welcome. This is where patients with relapsing forms
of
multiple sclerosis (MS) come when they're ready for a
multiple sclerosis treatment that is different.
Hear from people
who tried
TYSABRI
and were
glad they did.
TYSABRI is a prescription medication approved for patients with
relapsing forms of multiple sclerosis (MS), and is now indicated for
appropriate patients with Crohn's disease.
TYSABRI is indicated as monotherapy for the treatment of patients
with relapsing forms of multiple sclerosis to delay the accumulation of
physical disability and reduce the frequency of clinical exacerbations.
TYSABRI is generally recommended for patients who have had an inadequate
response to, or are unable to tolerate, alternate MS therapies.
TYSABRI is indicated for inducing and maintaining clinical response
and remission in adult patients with moderately to severely active Crohn's
disease (CD) with evidence of inflammation who have had an inadequate response
to, or are unable to tolerate, conventional CD therapies and inhibitors of
TNF-?.
In CD, TYSABRI should not be used in combination with
immunosuppressants or inhibitors of TNF-?.
